Stable gastric pentadecapeptide BPC 157 and bupivacaine

In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro

“…erefore, the noted evidence (BPC 157 markedly interacts with lidocaineinduced adverse effects) combines and extends the previous demonstration that BPC 157 counteracts bupivacaine cardiotoxicity [14] and can therefore be a potential antidote to amide local anesthetics. e noted counteraction of the bupivacaine toxicity (14), much like that of lidocaine, is quite indicative. Namely, bupivacaine has greater potential for direct cardiac toxicity than other agents, and thereby, a greater affinity for the inactive and resting sodium channel configurations and slower dissociation from these channels [46].…”

“…All local anesthetics carry a dose-dependent risk of possible CNS and cardiovascular toxicity [46]. erefore, the noted evidence (BPC 157 markedly interacts with lidocaineinduced adverse effects) combines and extends the previous demonstration that BPC 157 counteracts bupivacaine cardiotoxicity [14] and can therefore be a potential antidote to amide local anesthetics. e noted counteraction of the bupivacaine toxicity (14), much like that of lidocaine, is quite indicative.…”

“…Specific arguments to extend the use of BPC 157 against the adverse effects of local anesthetics, such as lidocaine, follow the BPC 157 counteraction of bupivacaine cardiotoxicity [14], bupivacaine-induced depolarisation in HEK293 cells [14], and drug-induced heart arrhythmias [15][16][17][18][19]. A similar generalization was already made with dopamine neuroleptics or prokinetics since BPC 157 counteracts the prolongation of the QTc interval after the daily administration of dopamine neuroleptics or prokinetics [19] much like neuroleptic-induced catalepsy and gastric ulcers [19][20][21][22].…”

“…us, we attempt to counteract lidocaine toxicity. Previously reported effective dose regimens of the pentadecapeptide BPC 157 [14][15][16][17][18][19], along with the NOS-inhibitor L-NAME and the NOS-substrate L-arginine, given alone and/or in combination, were administered after lidocaine application in rats or in an in vitro HEK293 cell model, showing the presence of endogenous voltage-gated potassium (K + ), sodium (Na + ), and calcium (Ca 2+ ) channels [42].…”

Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future

“…[1][2][3][4][5][6][7][8][9][10][11][12][13] Of particular notation in BPC 157 studies is that each organ lesion counteraction includes different noxious procedures but regularly the same dose regimen which enables to combine the beneficial effects consistently obtained. [1][2][3][4][5][6][7][8][9][10][11][12][13] Illustratively, beneficial activity in heart assay includes counteraction of the doxorubicin cardiomyopathy, 41 distinctive arrhythmias induced by digitalis, 42 hyperkalemia, 43 hypokalemia, 44 succinylcholine, 45 bupivacaine, 46 and neuroleptics. 47 Pleotropic beneficial activity based on the opposing relationship with alcohol and NSAIDs adverse effects In general cytoprotective/adaptive cytoprotection/organoprotection terms, and pleotropic range of the beneficial activities of BPC 157, and its opposing relationship with the alcohol and NSAIDs adverse effects, already reviewed, 8,11 this extension is quite logical.…”